FDA approves Roche’s “tumour agnostic” drug RozlytrekThe FDA has approved Roche’s Rozlytrek (entrectinib), a so-called “tumour agnostic” drug that is approved to key into certain mutations in Share XFDA approves Roche’s “tumour agnostic” drug Rozlytrekhttps://pharmaphorum.com/news/fda-approves-roches-tumour-agnostic-drug-rozlytrek/
AbbVie/Janssen win EU approval for two new Imbruvica usesEuropean regulators have approved AbbVie and Janssen’s Imbruvica (ibrutinib) in two expanded uses that broaden the use of Share XAbbVie/Janssen win EU approval for two new Imbruvica useshttps://pharmaphorum.com/news/eu-regulators-approve-two-new-uses-for-janssens-imbruvica/
AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatmentAstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this Share XAZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatmenthttps://pharmaphorum.com/news/az-msd-parp-inhibitor-ovarian-cancer/
Boehringer jumps on KRAS cancer drug bandwagon with MD AndersonBoehringer Ingelheim has become the latest pharma company to investigate KRAS as a potential target for cancer drugs, Share XBoehringer jumps on KRAS cancer drug bandwagon with MD Andersonhttps://pharmaphorum.com/news/boehringer-jumps-on-kras-cancer-drug-bandwagon-with-md-anderson/
AZ’s lung cancer drug Tagrisso gets boost from first line OS resultsAstraZeneca has announced figures confirming that its Tagrisso extends overall survival in patients with untreated non-small cell lung Share XAZ’s lung cancer drug Tagrisso gets boost from first line OS resultshttps://pharmaphorum.com/news/azs-key-cancer-drug-tagrisso-gets-further-boost-from-os-results/
MSD’s Keytruda plus chemo backed by NICE for lung cancerMerck & Co/MSD’s Keytruda can be provided via the Cancer Drugs Fund for first-line treatment of non-small cell Share XMSD’s Keytruda plus chemo backed by NICE for lung cancerhttps://pharmaphorum.com/news/msds-keytruda-plus-chemo-backed-by-nice-for-lung-cancer/
Sillajen explains Pexa-Vec trial failure – it was the rescue medsSouth Korean biotech Sillajen was hit hard last week when its oncolytic virus therapy Pexa-Vec failed a phase Share XSillajen explains Pexa-Vec trial failure – it was the rescue medshttps://pharmaphorum.com/news/sillajen-explains-pexa-vec-trial-failure-it-was-the-rescue-meds/
Roche scores with Tecentriq combo in first-line bladder cancerRoche’s Tecentriq has become the first checkpoint inhibitor to show a benefit in previously-untreated patients with bladder cancer Share XRoche scores with Tecentriq combo in first-line bladder cancerhttps://pharmaphorum.com/news/roche-scores-with-tecentriq-combo-in-first-line-bladder-cancer/
Daiichi Sankyo’s pexidartinib is first FDA-approved drug for rare tumourDaiichi Sankyo’s pexidartinib has become the first FDA-approved therapy for tenosynovial giant cell tumour (TGCT), a rare form Share XDaiichi Sankyo’s pexidartinib is first FDA-approved drug for rare tumourhttps://pharmaphorum.com/news/daiichi-sankyos-pexidartinib-is-first-fda-approved-drug-for-rare-tumour/
